Is Becton, Dickinson and Company (BDX) a good stock to buy?

Olyth's institutional analysis of BDX reveals an Altman Z-Score of 2.13 and a Piotroski F-Score of 8/9. These metrics, combined with its 5-year revenue trend ($21.84B most recent), help investors decide if BDX fits their risk profile.

What is the current P/E ratio for BDX?

As of the latest trading session, Becton, Dickinson and Company (BDX) has a trailing P/E ratio of 25.26.

Who is the CEO of Becton, Dickinson and Company?

The current Chief Executive Officer of Becton, Dickinson and Company is Thomas E. Polen Jr..

What was BDX's revenue for the last 5 years?

According to its latest income statements, Becton, Dickinson and Company reported annual revenues of $21.84B (2025), $20.18B (2024), $19.37B (2023), $18.87B (2022), $19.13B (2021) respectively.

Does BDX pay a dividend?

Becton, Dickinson and Company currently pays a dividend to its shareholders, with a trailing dividend yield of 2.26%.

How much debt and cash flow does BDX have?

In its latest reporting period, Becton, Dickinson and Company generated $2.67B in Free Cash Flow against a total debt load of $19.18B.

What is the Price-to-Book (P/B) ratio of Becton, Dickinson and Company?

The Price-to-Book (P/B) ratio for Becton, Dickinson and Company (BDX) is currently 1.76.

What is the Price-to-Sales (P/S) ratio of BDX?

Based on trailing twelve-month data, Becton, Dickinson and Company (BDX) trades at a Price-to-Sales (P/S) ratio of 2.57.

What is Becton, Dickinson and Company's Return on Equity (ROE)?

Becton, Dickinson and Company (BDX) has a Return on Equity (ROE) of 6.93%, representing its profitability relative to shareholder equity.

BDX

Becton, Dickinson and Company · Healthcare

155.68

0.23%(+0.36)

Market Open

Last Updated: — ET

52W L: $127.5952W H: $187.35

$155.18

CHG-11.19 (-6.73%)

H$169.06

L$152.97

VOL41M

BDX (1h)

Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Employees

70,000

IPO Date

1973-02-21

Beta

0.35

Websitewww.bd.com↗

BDX

When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight

BD Rolls Out Next-Gen Medication Dispensing System Across Europe

BD lanza al mercado europeo un sistema de dispensación de medicamentos con inteligencia artificial

BD bringt ein KI-gestütztes Medikamentenausgabesystem auf den europäischen Markt

BD lance un système de distribution de médicaments basé sur l'IA sur le marché européen

BD Launches AI-Enabled Medication Dispensing System to the European Market